Bank of Montreal Can Sells 721 Shares of Insmed, Inc. $INSM

Bank of Montreal Can cut its stake in Insmed, Inc. (NASDAQ:INSM) by 2.4% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 29,685 shares of the biopharmaceutical company’s stock after selling 721 shares during the period. Bank of Montreal Can’s holdings in Insmed were worth $2,987,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently modified their holdings of INSM. M&T Bank Corp increased its holdings in shares of Insmed by 4.7% in the first quarter. M&T Bank Corp now owns 3,293 shares of the biopharmaceutical company’s stock valued at $252,000 after purchasing an additional 147 shares in the last quarter. ORG Partners LLC increased its stake in shares of Insmed by 220.2% in the 2nd quarter. ORG Partners LLC now owns 285 shares of the biopharmaceutical company’s stock valued at $28,000 after buying an additional 196 shares during the period. Cullen Frost Bankers Inc. raised its position in shares of Insmed by 164.9% during the first quarter. Cullen Frost Bankers Inc. now owns 355 shares of the biopharmaceutical company’s stock worth $27,000 after acquiring an additional 221 shares during the last quarter. Nisa Investment Advisors LLC raised its position in shares of Insmed by 6.5% during the first quarter. Nisa Investment Advisors LLC now owns 3,761 shares of the biopharmaceutical company’s stock worth $287,000 after acquiring an additional 228 shares during the last quarter. Finally, Hilltop National Bank acquired a new position in shares of Insmed during the second quarter valued at $28,000.

Insider Buying and Selling

In other Insmed news, COO Roger Adsett sold 25,000 shares of the company’s stock in a transaction on Tuesday, August 19th. The shares were sold at an average price of $127.58, for a total transaction of $3,189,500.00. Following the sale, the chief operating officer owned 105,637 shares of the company’s stock, valued at approximately $13,477,168.46. This represents a 19.14% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Orlov S. Nicole Schaeffer sold 76,520 shares of Insmed stock in a transaction dated Friday, September 12th. The stock was sold at an average price of $145.45, for a total value of $11,129,834.00. Following the completion of the transaction, the insider directly owned 36,461 shares of the company’s stock, valued at approximately $5,303,252.45. This trade represents a 67.73% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 179,787 shares of company stock worth $26,428,149. Corporate insiders own 3.00% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on INSM. Morgan Stanley lifted their price objective on Insmed from $126.00 to $144.00 and gave the stock an “equal weight” rating in a research report on Thursday, August 21st. Jefferies Financial Group boosted their price target on shares of Insmed from $129.00 to $148.00 and gave the stock a “buy” rating in a research note on Wednesday, August 13th. Mizuho set a $196.00 price objective on shares of Insmed in a report on Wednesday, October 29th. Bank of America raised their price objective on shares of Insmed from $142.00 to $187.00 and gave the company a “buy” rating in a research note on Monday, October 27th. Finally, UBS Group upped their target price on shares of Insmed from $194.00 to $223.00 and gave the company a “buy” rating in a research report on Friday, October 31st. Nineteen equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $173.29.

Insmed Trading Up 0.4%

Shares of INSM stock opened at $194.39 on Thursday. The stock has a market cap of $41.46 billion, a price-to-earnings ratio of -34.04 and a beta of 1.05. The stock has a 50-day moving average of $160.42 and a 200-day moving average of $118.99. The company has a current ratio of 6.68, a quick ratio of 6.33 and a debt-to-equity ratio of 0.45. Insmed, Inc. has a 1-year low of $60.40 and a 1-year high of $197.08.

Insmed (NASDAQ:INSM) last posted its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported ($1.75) EPS for the quarter, missing analysts’ consensus estimates of ($1.35) by ($0.40). The company had revenue of $142.34 million during the quarter, compared to analyst estimates of $114.33 million. Insmed had a negative return on equity of 195.37% and a negative net margin of 259.82%.Insmed’s revenue was up 52.4% compared to the same quarter last year. During the same period in the prior year, the firm earned ($1.27) earnings per share. Insmed has set its FY 2025 guidance at EPS. On average, equities research analysts forecast that Insmed, Inc. will post -4.56 earnings per share for the current year.

Insmed Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.